$LSTA News
Last published 1d ago
- 1d agoLSTAGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - LISATA THERAPEUTICS INCEarnings Call TranscriptsWelcome to Guggenheim's, I guess this is our third annual Healthcare Innovations Conference here in Boston. Really pleased to be joined by Mireya Therapeutics, the I guess active ticker for the time being is under Lissat
- 2d agoLSTAMarea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of MedicineGlobeNewswirePart A of TYDAL-TIMI 78 Trial met all objectives, with statistically significant placebo-adjusted triglyceride reductions of 39.1%–45.5% across all three doses at Week 12 and up to 57.2% in participants with baseline
- 2d agoLSTAMarea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of MedicineGlobeNewswirePart A of TYDAL-TIMI 78 Trial met all objectives, with statistically significant placebo-adjusted triglyceride reductions of 39.1%–45.5% across all three doses at Week 12 and up to 57.2% in participants with baseline triglycerides ≥300 mg/dL
- 6d agoLSTAMarea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. ("Marea"), a subsidiary of Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), a
- 4w agoLSTATARSACHVLisata Therapeutics Appoints Jeff Farrow to Board of DirectorsGlobeNewswireLIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company") today announced the appointment of Jeffrey Farrow to its Board of Directors,
- 1mo agoLSTALisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid TumorsGlobeNewswireLIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company, today announced that the United
- 1mo agoLSTALisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private PlacementGlobeNewswireCombined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG)
- 3mo agoLSTALisata Therapeutics Provides Update Following Termination of Merger AgreementGlobeNewswireLisata has filed suit against Kuva Labs Inc. and its subsidiary seeking, among other things, damages for the benefit of its stockholders Lisata’s Board of Directors and management continues to evaluate strategic
- 5mo agoLSTALisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.GlobeNewswireLisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of
- 8mo agoLSTALisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.GlobeNewswireEach Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share Board of directors unanimously approved the
- 9mo agoLSTALisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for CertepetideGlobeNewswireBASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 9mo agoLSTALisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender OfferGlobeNewswireStockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium over the most recent
- 1y agoLSTALisata Therapeutics Wins 2025 BioTech Breakthrough Award for 'Overall BioPharma Solution of the Year'GlobeNewswireBASKING RIDGE, N.J. , Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 1y agoLSTALisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner CatalentGlobeNewswireBASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 1y agoLSTALisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025GlobeNewswireBASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 1y agoLSTALisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License AgreementGlobeNewswireCatalent gains global rights to evaluate certepetide and its analogs for use as SMARTag® payloads across multiple ADCs designed to address difficult-to-treat diseases Catalent's preclinical study results provide
- 1y agoLSTALisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX TrialGlobeNewswireResults to be presented at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions
- 1y agoLSTALisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireBASKING RIDGE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 1y agoLSTALisata Therapeutics, Inc. (LSTA) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoLSTALisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireCash runway extending into the fourth quarter of 2026 with no debt, funding current clinical programs through to their next data milestone Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE,
- 1y agoLSTALisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025GlobeNewswireBASKING RIDGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 1y agoLSTALisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data UpdateGlobeNewswireBASKING RIDGE, N.J. and SUBIACO, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies
- 1y agoLSTALisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for CertepetideGlobeNewswireNewly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extension This patent covers novel cyclic peptides and their use in treating solid tumors BASKING
- 1y agoLSTAPositive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata's Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic CancerGlobeNewswireASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentially Positive signal in progression-free survival and objective response rate observed in certepetide-treated
- 1y agoLSTALisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and DevelopmentGlobeNewswireExpanded alliance combines Lisata's drug development expertise with GATC's AI-powered Multiomics Advanced Technology® platform to accelerate and improve success rates of next-generation drug development Lisata to
- 1y agoLSTALisata Therapeutics to Present at the 2025 BIO International ConventionGlobeNewswireBASKING RIDGE, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 1y agoLSTALisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireEncouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025;Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 Cash runway extending into the third quarter
- 1y agoLSTALisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025GlobeNewswireBASKING RIDGE, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 1y agoLSTALisata Therapeutics Announces Research License with CatalentGlobeNewswireBASKING RIDGE, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 1y agoLSTALisata Therapeutics to Present at the Investival Showcase USAGlobeNewswireBASKING RIDGE, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 1y agoLSTALisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug DevelopmentGlobeNewswireStrategic collaboration harnesses GATC's proprietary Artificial Intelligence-powered, validated Multiomics Advanced Technology™ platform to rapidly optimize and derisk drug discovery and development, thereby
- 1y agoLSTALisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswirePromising preliminary Phase 2b (ASCEND) pancreatic cancer data (Cohort A) reported with Cohort B data anticipated in the coming months Enrollment completed in Qilu's Phase 2 trial evaluating certepetide for the
- 1y agoLSTALisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025GlobeNewswireBASKING RIDGE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 1y agoLSTALisata Therapeutics to Present at the 2025 BIO CEO & Investor ConferenceGlobeNewswireBASKING RIDGE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 1y agoLSTALisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal AdenocarcinomaGlobeNewswireCohort A data to be presented in a poster session at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Data reported positive trend in overall survival, including 4 complete responses
- 1y agoLSTALisata Therapeutics to Present at the 2025 Sequire Investor SummitGlobeNewswireBASKING RIDGE, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid
- 1y agoLSTALisata Therapeutics Announces Completion of Enrollment in the CENDIFOX TrialGlobeNewswireBASKING RIDGE, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid
- 1y agoLSTALisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor ImagingGlobeNewswireBASKING RIDGE, N.J. and HOUSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 1y agoLSTALisata Therapeutics Wins 2024 BioTech Breakthrough Award for 'Specialized BioTherapeutics Company of the Year'GlobeNewswireAward recognizes Lisata's data-driven approach and innovative therapies designed to address the unmet medical needs of patients with advanced solid tumors Annual BioTech Breakthrough Award is devoted to honoring
- 1y agoLSTALisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoLSTALisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireRobust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. 12, 2024 (GLOBE
- 2y agoLSTALisata Therapeutics and Valo Therapeutics Announce Preclinical Research CollaborationGlobeNewswireBASKING RIDGE, N.J. and HELSINKI, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid
- 2y agoLSTALisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024GlobeNewswireBASKING RIDGE, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and
- 2y agoLSTALisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor EventsGlobeNewswireBASKING RIDGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and
- 2y agoLSTALisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of EndometriosisGlobeNewswireBASKING RIDGE, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and
- 2y agoLSTALisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor EventsGlobeNewswireBASKING RIDGE, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 2y agoLSTALisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER TrialGlobeNewswireBASKING RIDGE, N.J., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 2y agoLSTALisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor EventsGlobeNewswireBASKING RIDGE, N.J. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 2y agoLSTALisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of CholangiocarcinomaGlobeNewswireBASKING RIDGE, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of
- 2y agoLSTALisata Therapeutics, Inc. (LSTA) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts